



Date:- March 25, 2024

To The Listing Department <b>National Stock Exchange of India Limited</b> Exchange Plaza, Bandra – Kurla Complex Bandra (East) <u>Mumbai – 400 051</u> <b>Stock Code : INDOCO-EQ</b>	To The Listing Department <b>Bombay Stock Exchange Limited</b> Floor 25, P. J. Towers, Dalal Street, <u>Mumbai – 400 001</u> <b>Stock Code : 532612</b>
---	---

Dear Sir/Madam,

**Subject: Commencement of Commercial Production**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Warren Remedies Private Limited, Wholly Owned Subsidiary of the Company has commenced its commercial production on March 24, 2024 from its Greenfield manufacturing facility located at Aurangabad, Maharashtra to manufacture Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (APIs).

Please find enclosed herewith press release in this regard. Kindly take the above information on record.

Thanking you,

Yours faithfully,

For Indoco Remedies Limited

Sundeep V. Bambolkar

Jt. Managing Director

DIN: 00176613



**INDOCO REMEDIES LIMITED**

Indoco House, 166, C.S.T. Road, Kalina, Santacruz (E), Mumbai 400098, India.  
Tel. No.: +91 22 6287 1000 / 6879 1250 ■ CIN: L85190MH1947PLC005913

www.indoco.com



# PRESS RELEASE

## **Warren Remedies Private Limited, a Wholly Owned Subsidiary of Indoco Remedies Limited commences commercial production of Pharmaceutical Intermediates**

**Mumbai, March 25, 2024:** Warren Remedies Private Limited, a Wholly Owned Subsidiary of Indoco Remedies Limited has commenced its commercial production on March 24, 2024 from its Greenfield manufacturing facility located at Aurangabad, Maharashtra to manufacture Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (APIs).

Commenting on this occasion, **Ms. Aditi Panandikar, Managing Director-Indoco Remedies Ltd.** said, “It gives us immense pleasure to announce that Warren Remedies Private Limited, Wholly Owned Subsidiary of Indoco Remedies has commenced its commercial production of Pharmaceutical Intermediates to cater to the needs of its customers. The said manufacturing facility will provide us requisite capabilities and edge in meeting demand of APIs.”

### **About Indoco Remedies Limited:**

Indoco is a fully integrated, research-oriented pharmaceutical company with presence in 55 countries. The Company’s turnover is US\$ 200 million with a human capital of 6000 employees, including over 300 skilled scientists and Field Staff who are the strength of the organization.

The Company has 9 manufacturing facilities, 6 for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 109 million prescriptions annually from over 3,00,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritional, Cardiovascular, Anti-Diabetics, Pain Management, Gyneacology etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM 69, Methycal, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit [www.indoco.com](http://www.indoco.com)

### **For Media Inquiries Please Contact:**

E-mail: [corpcom@indoco.com](mailto:corpcom@indoco.com)